 |
PDBsum entry 5m32
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
230 a.a.
|
 |
|
|
|
|
|
|
|
234 a.a.
|
 |
|
|
|
|
|
|
|
234 a.a.
|
 |
|
|
|
|
|
|
|
233 a.a.
|
 |
|
|
|
|
|
|
|
234 a.a.
|
 |
|
|
|
|
|
|
|
232 a.a.
|
 |
|
|
|
|
|
|
|
233 a.a.
|
 |
|
|
|
|
|
|
|
221 a.a.
|
 |
|
|
|
|
|
|
|
204 a.a.
|
 |
|
|
|
|
|
|
|
196 a.a.
|
 |
|
|
|
|
|
|
|
200 a.a.
|
 |
|
|
|
|
|
|
|
213 a.a.
|
 |
|
|
|
|
|
|
|
216 a.a.
|
 |
|
|
|
|
|
|
|
202 a.a.
|
 |
|
|
|
|
|
|
|
347 a.a.
|
 |
|
|
|
|
|
|
|
333 a.a.
|
 |
|
|
|
|
|
|
|
361 a.a.
|
 |
|
|
|
|
|
|
|
348 a.a.
|
 |
|
|
|
|
|
|
|
363 a.a.
|
 |
|
|
|
|
|
|
|
332 a.a.
|
 |
|
|
|
|
|
|
|
230 a.a.
|
 |
|
|
|
|
|
|
|
155 a.a.
|
 |
|
|
|
|
|
|
|
364 a.a.
|
 |
|
|
|
|
|
|
|
415 a.a.
|
 |
|
|
|
|
|
|
|
375 a.a.
|
 |
|
|
|
|
|
|
|
206 a.a.
|
 |
|
|
|
|
|
|
|
75 a.a.
|
 |
|
|
|
|
|
|
|
101 a.a.
|
 |
|
|
|
|
|
|
|
259 a.a.
|
 |
|
|
|
|
|
|
|
26 a.a.
|
 |
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Human 26s proteasome in complex with oprozomib
|
|
Structure:
|
 |
Proteasome subunit alpha type-2. Chain: a, o. Synonym: macropain subunit c3,multicatalytic endopeptidase complex subunit c3,proteasome component c3. Proteasome subunit alpha type-4. Chain: b, p. Synonym: macropain subunit c9,multicatalytic endopeptidase complex subunit c9,proteasome component c9,proteasome subunit l. Proteasome subunit alpha type-7.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Synthetic: yes. Synthetic construct. Organism_taxid: 32630
|
|
Authors:
|
 |
D.Haselbach,J.Schrader,F.Lambrecht,F.Henneberg,A.Chari,H.Stark
|
|
Key ref:
|
 |
D.Haselbach
et al.
(2017).
Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs.
Nat Commun,
8,
15578.
PubMed id:
|
 |
|
Date:
|
 |
|
14-Oct-16
|
Release date:
|
05-Jul-17
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P25787
(PSA2_HUMAN) -
Proteasome subunit alpha type-2 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
234 a.a.
230 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P25789
(PSA4_HUMAN) -
Proteasome subunit alpha type-4 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
261 a.a.
234 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
O14818
(PSA7_HUMAN) -
Proteasome subunit alpha type-7 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
248 a.a.
234 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P28066
(PSA5_HUMAN) -
Proteasome subunit alpha type-5 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
241 a.a.
233 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P25786
(PSA1_HUMAN) -
Proteasome subunit alpha type-1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
263 a.a.
234 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P25788
(PSA3_HUMAN) -
Proteasome subunit alpha type-3 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
255 a.a.
232 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P60900
(PSA6_HUMAN) -
Proteasome subunit alpha type-6 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
246 a.a.
233 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q99436
(PSB7_HUMAN) -
Proteasome subunit beta type-7 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
277 a.a.
221 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P49720
(PSB3_HUMAN) -
Proteasome subunit beta type-3 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
205 a.a.
204 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P49721
(PSB2_HUMAN) -
Proteasome subunit beta type-2 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
201 a.a.
196 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P28074
(PSB5_HUMAN) -
Proteasome subunit beta type-5 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
263 a.a.
200 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P20618
(PSB1_HUMAN) -
Proteasome subunit beta type-1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
241 a.a.
213 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P28070
(PSB4_HUMAN) -
Proteasome subunit beta type-4 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
264 a.a.
216 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P28072
(PSB6_HUMAN) -
Proteasome subunit beta type-6 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
239 a.a.
202 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P35998
(PRS7_HUMAN) -
26S proteasome regulatory subunit 7 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
433 a.a.
347 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P62191
(PRS4_HUMAN) -
26S proteasome regulatory subunit 4 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
440 a.a.
333 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P43686
(PRS6B_HUMAN) -
26S proteasome regulatory subunit 6B from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
418 a.a.
361 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P62333
(PRS10_HUMAN) -
26S proteasome regulatory subunit 10B from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
389 a.a.
348 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P17980
(PRS6A_HUMAN) -
26S proteasome regulatory subunit 6A from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
439 a.a.
363 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P62195
(PRS8_HUMAN) -
26S proteasome regulatory subunit 8 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
406 a.a.
332 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q99460
(PSMD1_HUMAN) -
26S proteasome non-ATPase regulatory subunit 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
953 a.a.
230 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
O43242
(PSMD3_HUMAN) -
26S proteasome non-ATPase regulatory subunit 3 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
534 a.a.
155 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
O00232
(PSD12_HUMAN) -
26S proteasome non-ATPase regulatory subunit 12 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
456 a.a.
364 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
O00231
(PSD11_HUMAN) -
26S proteasome non-ATPase regulatory subunit 11 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
422 a.a.
415 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q15008
(PSMD6_HUMAN) -
26S proteasome non-ATPase regulatory subunit 6 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
389 a.a.
375 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P51665
(PSMD7_HUMAN) -
26S proteasome non-ATPase regulatory subunit 7 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
324 a.a.
206 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q9UNM6
(PSD13_HUMAN) -
26S proteasome non-ATPase regulatory subunit 13 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
376 a.a.
75 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P55036
(PSMD4_HUMAN) -
26S proteasome non-ATPase regulatory subunit 4 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
377 a.a.
101 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
|
|
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z, a, b:
E.C.3.4.25.1
- proteasome endopeptidase complex.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Cleavage at peptide bonds with very broad specificity.
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chain q:
E.C.3.4.19.-
- ?????
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
Nat Commun
8:15578
(2017)
|
|
PubMed id:
|
|
|
|
|
| |
|
Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs.
|
|
D.Haselbach,
J.Schrader,
F.Lambrecht,
F.Henneberg,
A.Chari,
H.Stark.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The proteasome holoenzyme is the major non-lysosomal protease; its proteolytic
activity is essential for cellular homeostasis. Thus, it is an attractive target
for the development of chemotherapeutics. While the structural basis of core
particle (CP) inhibitors is largely understood, their structural impact on the
proteasome holoenzyme remains entirely elusive. Here, we determined the
structure of the 26S proteasome with and without the inhibitor Oprozomib. Drug
binding modifies the energy landscape of conformational motion in the proteasome
regulatory particle (RP). Structurally, the energy barrier created by Oprozomib
triggers a long-range allosteric regulation, resulting in the stabilization of a
non-productive state. Thereby, the chemical drug-binding signal is converted,
propagated and amplified into structural changes over a distance of more than
150 Å from the proteolytic site to the ubiquitin receptor Rpn10. The direct
visualization of changes in conformational dynamics upon drug binding allows new
ways to screen and develop future allosteric proteasome inhibitors.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
| | |